These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 15979994

  • 1. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G.
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [Abstract] [Full Text] [Related]

  • 2. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 3. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [Abstract] [Full Text] [Related]

  • 4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 5. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P.
    Hum Reprod Update; 2006 Sep; 12(4):333-40. PubMed ID: 16567347
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS.
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [Abstract] [Full Text] [Related]

  • 7. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 8. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P.
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [Abstract] [Full Text] [Related]

  • 9. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
    Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P.
    Fertil Steril; 2007 Nov; 88(5):1382-8. PubMed ID: 17445806
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 11. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M, Maldonado LG, de Souza Bonetti TC, de Almeida Ferreira Braga DP, Iaconelli A, Borges E.
    Fertil Steril; 2010 Jun 01; 94(1):167-72. PubMed ID: 19342035
    [Abstract] [Full Text] [Related]

  • 12. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER.
    Fertil Steril; 2006 Dec 01; 86(6):1682-7. PubMed ID: 17074344
    [Abstract] [Full Text] [Related]

  • 13. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun 01; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 14. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG.
    J Clin Endocrinol Metab; 2002 Feb 01; 87(2):709-15. PubMed ID: 11836309
    [Abstract] [Full Text] [Related]

  • 15. Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists.
    Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P.
    Hum Reprod; 2006 Apr 01; 21(4):1012-7. PubMed ID: 16339166
    [Abstract] [Full Text] [Related]

  • 16. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb 01; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 17. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G, Kolibianakis EM, Papanikolaou EG, Diedrich K, Van Steirteghem A, Devroey P, Ejdrup Bredkjaer H, Humaidan P.
    Fertil Steril; 2007 Sep 01; 88(3):616-21. PubMed ID: 17451691
    [Abstract] [Full Text] [Related]

  • 18. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM.
    J Reprod Med; 2014 Sep 01; 59(1-2):63-8. PubMed ID: 24597289
    [Abstract] [Full Text] [Related]

  • 19. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct 01; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 20. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel L, Devroey P, Fatemi H.
    Hum Reprod; 2012 Nov 01; 27(11):3259-72. PubMed ID: 22930004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.